# US 2006/0154314 A9 · GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154314 A9
- Document ID: US20060154314A9
- Status: Published application
- Kind: A9
- Application number: 10/917,844
- Filed: 2004-08-13
- Published: 2006-07-13
- Earliest claimed: 2001-08-28
- Assignees: Allergan Sales, Inc.
- Inventors: Lance Steward; Marcella Gilmore; Kei Aoki
- Web page: https://patentgrep.com/patent/US20060154314A9

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/001: {by chemical synthesis}
- C07K 14/435: from animals; from humans
- C07K 14/43595: {from coelenteratae, e.g. medusae}
- C12N 9/52: derived from bacteria {or Archaea}
- C12Q 1/37: involving peptidase or proteinase
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- G01N 33/56911: {Bacteria}
- C07K 2319/00: Fusion polypeptide
- G01N 2333/33: from Clostridium (G)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple.

## Claims

### Claim 1

Method of determining clostridial toxin protease activity, comprising the steps of:
(a) treating with a sample, in solution phase under conditions suitable for clostridial toxin protease activity, a tagged toxin substrate comprising
(i) a fluorescent protein;
(ii) a first partner of an affinity couple; and
(iii) a clostridial toxin recognition sequence comprising a cleavage site,
where the cleavage site intervenes between said fluorescent protein and said first partner of the affinity couple, such that a fluorescent cleavage product is generated when clostridial toxin is present in said sample;
(b) contacting said treated sample with a second partner of the affinity couple, thereby forming stable complexes comprising said first and second partners of said affinity couple; and
(c) assaying the presence or amount of said fluorescent cleavage product in said treated sample, thereby determining clostridial toxin protease activity

### Claim 2 (depends on 1)

The method of claim 1, wherein said fluorescent protein is selected from the group green fluorescent protein (GFP), blue fluorescent protein (BFP), cyan fluorescent protein (CFP), yellow fluorescent protein (YFP) and red fluorescent protein (RFP).

### Claim 3 (depends on 2)

The method of claim 2, wherein said fluorescent protein is GFP.

### Claim 4 (depends on 1, 2, 3)

The method of claim 1, 2 or 3, wherein said first partner of the affinity couple is selected from the group histidine tag, glutathione-S-transferase, maltose-binding protein, a biotinylation sequence, streptavidin, S peptide, S protein, FLAG, hemagluttinin (HA), c-myc and AU1.

### Claim 5 (depends on 4)

The method of claim 4, wherein said first partner of the affinity couple is a histidine tag.

### Claim 6 (depends on 1)

The method of claim 1, wherein said recognition sequence is a botulinum toxin recognition sequence.

### Claim 7 (depends on 6)

The method of claim 6, wherein said botulinum toxin recognition sequence comprises a portion of SNAP-25.

### Claim 8 (depends on 7)

The method of claim 7, wherein said portion of SNAP-25 is residues 134 to 206 of SEQ ID NO: 90.

### Claim 9 (depends on 6)

The method of claim 6, wherein said recognition sequence is a BoNT/A recognition sequence.

### Claim 10 (depends on 9)

The method of claim 9, wherein said BoNT/A recognition sequence comprises at least six consecutive residues of SNAP-25, said six consecutive residues comprising Gln-Arg.

### Claim 11 (depends on 6)

The method of claim 6, wherein said recognition sequence is a BoNT/B recognition sequence.

### Claim 12 (depends on 11)

The method of claim 11, wherein said BoNT/B recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Gln-Phe.

### Claim 13 (depends on 6)

The method of claim 6, wherein said recognition sequence is a BoNT/C1 recognition sequence.

### Claim 14 (depends on 13)

The method of claim 13, wherein said BoNT/C1 recognition sequence comprises at least six consecutive residues of syntaxin, said six consecutive residues comprising Lys-Ala.

### Claim 15 (depends on 13)

The method of claim 13, wherein said BoNT/C1 recognition sequence comprises at least six consecutive residues of SNAP-25, said six consecutive residues comprising Arg-Ala.

### Claim 16 (depends on 6)

The method of claim 6, wherein said recognition sequence is a BoNT/D recognition sequence.

### Claim 17 (depends on 16)

The method of claim 16, wherein said BoNT/D recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Lys-Leu.

### Claim 18 (depends on 6)

The method of claim 6, wherein said recognition sequence is a BoNT/E recognition sequence.

### Claim 19 (depends on 18)

The method of claim 18, wherein said BoNT/E recognition sequence comprises at least six consecutive residues of SNAP-25, said six consecutive residues comprising Arg-Ile.

### Claim 20 (depends on 6)

The method of claim 6, wherein said recognition sequence is a BoNT/F recognition sequence.

### Claim 21 (depends on 20)

The method of claim 20, wherein said BoNT/F recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Gln-Lys.

### Claim 22 (depends on 6)

The method of claim 6, wherein said recognition sequence is a BoNT/G recognition sequence.

### Claim 23 (depends on 22)

The method of claim 22, wherein said BoNT/G recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Ala-Ala.

### Claim 24 (depends on 1)

The method of claim 1, wherein said recognition sequence is a TeNT recognition sequence.

### Claim 25 (depends on 24)

The method of claim 24, wherein said TeNT recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Gln-Phe.

### Claim 26 (depends on 1)

The method of claim 1, wherein said substrate is cleaved with an activity of at least 1 nanomole/minute/milligram toxin.

### Claim 27 (depends on 1)

The method of claim 1, wherein said substrate is cleaved with an activity of at least 100 nanomoles/minute/milligram toxin.

### Claim 28 (depends on 1)

The method of claim 1, wherein said substrate is cleaved with an activity of at least 1000 nanomoles/minute/milligram toxin.

### Claim 29 (depends on 1)

The method of claim 1, wherein said second partner of the affinity couple is immobilized.

### Claim 30 (depends on 1, 29)

The method of claim 1 or 29, wherein said second partner of the affinity couple comprises cobalt (Co2+).

### Claim 31 (depends on 1, 29)

The method of claim 1 or 29, wherein said second partner of the affinity couple comprises nickel (Ni2+).

### Claim 32 (depends on 1)

The method of claim 1, further comprising separating said fluorescent cleavage product from said stable complexes prior to step (d).

### Claim 33 (depends on 32)

The method of claim 32, wherein said separating comprises applying said treated sample to a column, wherein said second partner of the affinity couple is immobilized on said column.

### Claim 34 (depends on 32)

The method of claim 32, wherein said separating comprises applying said treated sample to a filter plate, wherein said second partner of the affinity couple is immobilized on said filter plate.

### Claim 35 (depends on 1)

The method of claim 1, further comprising
(e) assaying the amount of uncleaved tagged toxin substrate in said treated sample.

### Claim 36 (depends on 1)

The method of claim 1, wherein said sample is isolated clostridial toxin.

### Claim 37 (depends on 1)

The method of claim 1, wherein said sample is isolated clostridial light chain.

### Claim 38 (depends on 1)

The method of claim 1, wherein said sample is a formulated clostridial toxin product.

### Claim 39 (depends on 38)

The method of claim 38, wherein said formulated product is a formulated BoNT/A product.

### Claim 40 (depends on 1)

The method of claim 1, wherein said sample is a whole or partially purified cellular extract containing recombinantly expressed clostridial toxin.

### Claim 41

A nucleic acid molecule, comprising a nucleotide sequence that encodes a SNAP-25 substrate comprising
(i) a green fluorescent protein;
(ii) a first partner of an affinity couple; and
(iii) a portion of SNAP-25 that comprises a BoNT/A, BoNT/C1 or BoNT/E recognition sequence comprising a cleavage site, wherein said cleavage site intervenes between said green fluorescent protein and said first partner of the affinity couple.

### Claim 42 (depends on 41)

The nucleic acid molecule of claim 41, wherein said first partner of the affinity couple is selected from the group histidine tag, glutathione-S-transferase, maltose-binding protein, a biotinylation sequence, streptavidin, S peptide, S protein, FLAG; hemagluttinin (HA), c-myc and AU1.

### Claim 43 (depends on 42)

The nucleic acid molecule of claim 42, wherein said first partner of the affinity couple is said histidine tag.

### Claim 44 (depends on 41)

The nucleic acid molecule of claim 41, wherein said portion of SNAP-25 comprises residues 134 to 206 of SEQ ID NO: 90.

### Claim 45 (depends on 44)

The nucleic acid molecule of claim 44, wherein said portion of SNAP-25 is residues 134 to 206 of SEQ ID NO: 90.

### Claim 46 (depends on 41)

The nucleic acid molecule of claim 41, wherein said recognition sequence is a BoNT/A recognition sequence.

### Claim 47 (depends on 41)

The nucleic acid molecule of claim 41, wherein said recognition sequence is a BoNT/C1 recognition sequence.

### Claim 48 (depends on 41)

The nucleic acid molecule of claim 41, wherein said recognition sequence is a BoNT/E recognition sequence.

### Claim 49 (depends on 41)

The nucleic acid molecule of claim 41, wherein said substrate can be cleaved with an activity of at least 1 nanomole/minute/milligram toxin.

### Claim 50 (depends on 41)

The nucleic acid molecule of claim 41, wherein said substrate can be cleaved with an activity of at least 100 nanomoles/minute/milligram toxin.

### Claim 51 (depends on 41)

The nucleic acid molecule of claim 41, wherein said substrate can be cleaved with an activity of at least 1000 nanomoles/minute/milligram toxin.

### Claim 52

A nucleic acid molecule, comprising a nucleotide sequence encoding a tagged toxin substrate, said tagged toxin substrate comprising:
(i) a fluorescent protein;
(ii) a first partner of an affinity couple; and
(iii) a clostridial toxin recognition sequence comprising a cleavage site, where said cleavage site intervenes between said fluorescent protein and said first partner of the affinity couple.

### Claim at position 53 (depends on 52)

53 The nucleic acid molecule of claim 52, wherein said fluorescent protein is selected from the group green fluorescent protein (GFP), blue fluorescent protein (BFP), cyan fluorescent protein (CFP), yellow fluorescent protein (YFP) and red fluorescent protein (RFP).

### Claim 54 (depends on 53)

The nucleic acid molecule of claim 53, wherein said fluorescent protein is green fluorescent protein (GFP).

### Claim 55 (depends on 52, 53, 54)

The nucleic acid molecule of claim 52, 53 or 54, wherein said first partner of the affinity couple is selected from the group histidine tag, glutathione-S-transferase, maltose-binding protein, a biotinylation sequence, streptavidin, S peptide, S protein, FLAG, hemagluttinin (HA), c-myc and AU1.

### Claim 56 (depends on 55)

The nucleic acid molecule of claim 55, wherein said first partner of the affinity couple is a histidine tag.

### Claim 57 (depends on 52)

The nucleic acid molecule of claim 52, wherein said recognition sequence is a botulinum toxin recognition sequence.

### Claim 58 (depends on 57)

The nucleic acid molecule of claim 57, wherein said botulinum toxin recognition sequence comprises a portion of SNAP-25.

### Claim 59 (depends on 58)

The nucleic acid molecule of claim 58, wherein said portion of SNAP-25 is residues 134 to 206 of SEQ ID NO: 90.

### Claim 60 (depends on 57)

The nucleic acid molecule of claim 57, wherein said recognition sequence is a BoNT/A recognition sequence.

### Claim 61 (depends on 60)

The nucleic acid molecule of claim 60, wherein said BoNT/A recognition sequence comprises at least six consecutive residues of SNAP-25, said six consecutive residues comprising Gln-Arg.

### Claim 62 (depends on 57)

The nucleic acid molecule of claim 57, wherein said recognition sequence is a BoNT/B recognition sequence.

### Claim 63 (depends on 62)

The nucleic acid molecule of claim 62, wherein said BoNT/B recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Gln-Phe.

### Claim 64 (depends on 57)

The nucleic acid molecule of claim 57, wherein said recognition sequence is a BoNT/C1 recognition sequence.

### Claim 65 (depends on 64)

The nucleic acid molecule of claim 64, wherein said BoNT/C1 recognition sequence comprises at least six consecutive residues of syntaxin, said six consecutive residues comprising Lys-Ala.

### Claim 66 (depends on 64)

The nucleic acid molecule of claim 64, wherein said BoNT/C1 recognition sequence comprises at least six consecutive residues of SNAP-25, said six consecutive residues comprising Arg-Ala.

### Claim 67 (depends on 57)

The nucleic acid molecule of claim 57, wherein said recognition sequence is a BoNT/D recognition sequence.

### Claim 68 (depends on 67)

The nucleic acid molecule of claim 67, wherein said BoNT/D recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Lys-Leu.

### Claim 69 (depends on 57)

The nucleic acid molecule of claim 57, wherein said recognition sequence is a BoNT/E recognition sequence.

### Claim 70 (depends on 69)

The nucleic acid molecule of claim 69, wherein said BoNT/E recognition sequence comprises at least six consecutive residues of SNAP-25, said six consecutive residues comprising Arg-Ile.

### Claim 71 (depends on 57)

The nucleic acid molecule of claim 57, wherein said recognition sequence is a BoNT/F recognition sequence.

### Claim 72 (depends on 71)

The nucleic acid molecule of claim 71, wherein said BoNT/F recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Gln-Lys.

### Claim 73 (depends on 57)

The nucleic acid molecule of claim 57, wherein said recognition sequence is a BoNT/G recognition sequence.

### Claim 74 (depends on 73)

The nucleic acid molecule of claim 73, wherein said BoNT/G recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Ala-Ala.

### Claim 75 (depends on 52)

The nucleic acid molecule of claim 52, wherein said recognition sequence is a TeNT recognition sequence.

### Claim 76 (depends on 75)

The nucleic acid molecule of claim 75, wherein said TeNT recognition sequence comprises at least six consecutive residues of VAMP, said six consecutive residues comprising Gln-Phe.

### Claim 77 (depends on 52)

The nucleic acid molecule of claim 52, wherein said substrate can be cleaved with an activity of at least 1 nanomole/minute/milligram toxin.

### Claim 78 (depends on 52)

The nucleic acid molecule of claim 52, wherein said substrate can be cleaved with an activity of at least 100 nanomoles/minute/milligram toxin.

### Claim 79 (depends on 52)

The nucleic acid molecule of claim 52, wherein said substrate can be cleaved with an activity of at least 1000 nanomoles/minute/milligram toxin.
